PATENT LICENSE AGREEMENT – EXCLUSIVEPublic Health Service • November 30th, 2020 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
ContractJune 3rd, 2009
Upon execution of an Implementing Letter in the form attached which specifies the materials to be transferred, this organization agrees to be bound by the terms of the attached Uniform Biological Material Transfer Agreement (“UBMTA”) published in the Federal Register on March 8, 1995.
NIH Publishing Agreement & Manuscript Cover SheetNih Publishing Agreement • August 6th, 2008
By signing this Cover Sheet, the Author, on behalf of NIH, agrees to the provisions set out below, which modify and supersede, solely with respect to NIH, any conflicting provisions that are in the Publisher’s standard copyright agreement (the “Publisher’s Agreement”). If a Publisher’s Agreement is attached, execution of this Cover Sheet constitutes an execution of the Publisher’s Agreement, subject to the provisions and conditions of this Cover Sheet.
BIOLOGICAL MATERIALS LICENSE AGREEMENT INTERNAL USE ONLY This Agreement is based on the model Biological Materials Internal Use Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the...Public Health Service • March 26th, 2019 • District of Columbia
The Licensee desires to obtain a license from the IC to use the Materials provided under this Agreement in its commercial research or product development and marketing activities. The Licensee represents that it has the facilities, personnel, and expertise to use the Materials or the Licensed Products for commercial purposes and agrees to expend reasonable efforts and resources to develop the Materials or the Licensed Products for commercial use or commercial research.
COMMERCIAL EVALUATION - BIOLOGICAL MATERIALS LICENSE AGREEMENTPublic Health Service • May 5th, 2020
NON-EXCLUSIVE PATENT LICENSE AGREEMENT FOR INTERNAL RESEARCH USEPublic Health Service • May 5th, 2020 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), Appendix D (Shipping Information) and Appendix E (Royalty Payment Options).
1PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • November 13th, 2018 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
This Agreement is based on the model Cost Sharing Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and...Public Health Service • October 22nd, 2015 • District of Columbia
COMMERCIAL EVALUATION LICENSE AGREEMENTPublic Health Service • May 5th, 2020
Commercial Internal Research Software License AgreementResearch Software License Agreement • March 26th, 2019 • District of Columbia
This Agreement is based on the model Interinstitutional Institution Lead Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for...Public Health Service • April 10th, 2018 • District of Columbia
In the course of fundamental research programs at the IC, under a HHS funding agreement (Grant/Contract No. ____________), ____________________ (Inventor(s)) made or reduced to practice certain inventions which are included within the Patent Rights, as defined in Paragraph 2.2.
BIOLOGICAL MATERIALS LICENSE AGREEMENTPublic Health Service • March 26th, 2019
START-UP PATENT LICENSE AGREEMENT – EXCLUSIVEPatent License Agreement • April 29th, 2015 • District of Columbia
This Start-Up Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
THE NATIONAL INSTITUTES OF HEALTH START-UP EXCLUSIVE EVALUATION OPTION LICENSE AGREEMENTExclusive Evaluation Option License Agreement • April 29th, 2015 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852‑3804, U.S.A. and ____________________ the (Licensee), a corporation of ____________________, having an office at ________________________________________.
This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and...Public Health Service • March 26th, 2019
This is the amendment (“ Amendment”) of the agreement by and between the IC and Licensee having an effective date of and having IC Reference Number L-XXX-200X/X (“Agreement”). This Amendment, having IC Reference Number L-XXX-200X/X includes, in addition to the amendments made below,
PUBLIC HEALTH SERVICE START-UP PATENT LICENSE AGREEMENT – EXCLUSIVEPublic Health Service • May 5th, 2020 • District of Columbia
This Start-Up Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
INTERINSTITUTIONAL AGREEMENT IC-LEADPublic Health Service • February 16th, 2017 • District of Columbia
Simple Letter Agreement for the Transfer of MaterialsSimple Letter Agreement • July 9th, 2002
In response to RECIPIENT’s request for the MATERIAL the PROVIDER asks that the RECIPIENT and the RECIPIENT SCIENTIST agree to the following before the RECIPIENT receives the MATERIAL:
MODEL LICENSE AGREEMENT FOR USE BY NON-PROFITS: Providing Rights to NIH Technologies for Distribution and Sale of Products for Neglected Tropical Diseases, HIV, TB and MalariaModel License Agreement • September 15th, 2017
LICENSEE QUALIFICATIONS: Not-for-profit institutions such as Product Development Partnerships (PDP) and Non-Government Organizations (NGOs) with a demonstrated commitment to diligence in providing broad global access to technologies, products and services consistent with an acceptable Development Plans.
STARTUP LICENSE AGREEMENTSStartup License Agreements • October 19th, 2015
Start-Up Licenses will be offered under the terms outlined below beginning October 1, 2015 with the offer ending on September 30, 2016, at which time the program will be evaluated for its success and possible extension.
THE National Institutes of Health BIOLOGICAL MATERIALS LICENSE AGREEMENT INTERNAL USE ONLYLicense Agreement • June 5th, 2012 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852‑3804, U.S.A. and ____________________ the (“Licensee”), a corporation of ____________________, having an office at ________________________________________.
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTPublic Health Service • March 24th, 2016 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Material Transfer Agreement for the Transfer of Organisms (MTA-TO) to Academic/ Not-for-Profit OrganizationsMaterial Transfer Agreement • August 26th, 2020
This is in response to RECIPIENT’s request for the MATERIAL (specifically, the name of the gene or allele mutation that makes the organism(s) unique)__________________________________________________________
COMMERCIAL EVALUATION LICENSE AGREEMENTCommercial Evaluation License Agreement • August 7th, 2012
This Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A. and the (“Licensee”), a corporation of , having an office at
PUBLIC HEALTH SERVICE MATERIAL TRANSFER AGREEMENTPublic Health Service Material Transfer Agreement • June 8th, 2001
This Material Transfer Agreement ("MTA") has been adopted for use by the National Institutes of Health ("NIH"), the Food and Drug Administration ("FDA"), and the Centers for Disease Control and Prevention ("CDC"), collectively referred to herein as the United States Public Health Service ("PHS") within the Department of Health and Human Services ("DHHS"), in all transfers of research material ("Research Material") whether PHS is identified below as its Provider or Recipient.
THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT – EXCLUSIVEHealth Patent License Agreement • May 5th, 2020 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
NATIONAL INSTITUTES OF HEALTH MATERIALS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTCooperative Research • August 7th, 2012
This Materials Cooperative Research and Development Agreement (“M-CRADA”) has been adopted for use by the Institutes and Centers (“ICs”) of the National Institutes of Health (“NIH”) for transfers of essential research material(s) from collaborators (hereinafter “Collaborator Research Material”) not otherwise reasonably available for NIH research. It consists of a copy of the NIH Model M-CRADA, a Signature Page, a Contacts Page, and a Summary Page. The research plan (“Research Plan”) is attached as Appendix A and all changes to this model agreement are collected in Appendix B. Appendices A and B are incorporated herein by reference. This M-CRADA involves no exchange of personnel or of any resources other than as described in Appendix A. This M-CRADA is made under authority of the Federal Technology Transfer Act, 15 U.S.C. § 3710a, and is governed by its terms.
NATIONAL INSTITUTES OF HEALTHCost-Sharing Agreement • May 5th, 2020 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) and agency within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852‑3804, U.S.A and ________________________________, hereinafter referred to as the “Institution”, having an address at ________________________________.
THE NATIONAL INSTITUTES OF HEALTH INTERINSTITUTIONAL AGREEMENT INSTITUTION-LEADHealth Interinstitutional Agreement • December 5th, 2012 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A and , hereinafter referred to as the “Institution”, having an address at .
Memorandum of UnderstandingAugust 26th, 2020
This Memorandum Of Understanding (hereinafter "Agreement"), effective July 1, 1999, by and between the Public Health Service of the U.S. Department of Health and Human Services as represented by the Office of Technology Transfer, having an address at National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852 ("PHS") and E.I. DuPont de Nemours and Company, a Delaware corporation having a principal place of business at 1008 Market Street, Wilmington, Delaware 19898 ("DuPont"). PHS and DuPont are referred to herein as the "Parties".
NON-EXCLUSIVE PATENT LICENSE AGREEMENT FOR INTERNAL RESEARCH USENon-Exclusive Patent License Agreement • February 14th, 2013 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), Appendix D (Shipping Information) and Appendix E (Royalty Payment Options). The Parties to this Agreement are:
CONFIDENTIAL DISCLOSURE AGREEMENTConfidential Disclosure Agreement • October 20th, 2015
This Agreement is made by and between the (IC Name) ("IC"), through the (IC Office Name), which is located at (IC Office address), and the company indicated below (hereinafter "Company").
THE NATIONAL INSTITUTES OF HEALTH BIOLOGICAL MATERIALS LICENSE AGREEMENTBiological Materials License Agreement • May 5th, 2020 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852‑3804, U.S.A. and ____________________ (the “Licensee”), a corporation of ____________________, having an office at ________________________________________.
NATIONAL INSTITUTES OF HEALTH COST-SHARING AGREEMENTSharing Agreement • December 5th, 2012 • District of Columbia
This Agreement is entered into between the National Institutes of Health (“NIH”) and agency within the Department of Health and Human Services (“HHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A and
National Institutes of HealthMarch 26th, 2019
This is the ____ amendment (“_____ Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) within the Department of Health and Human Services (“HHS”), and ____ having an effective date of ____ and having NIH Reference Number L-XXX-200X/X (“Agreement”). This ___ Amendment, having NIH Reference Number L‑XXX‑200X/X, is made between the NIH through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and ______________, having an office at ________________________________________________ (the “Licensee”). This ___ Amendment includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Shipping Information) and 3) Attachment 2 (Royalty Payment Information).
